Th1Th17<inf>CM</inf> lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment

Bibiana Quirant-Sánchez, Silvia Presas-Rodriguez, María José Mansilla, Aina Teniente-Serra, José V. Hervás-García, Luis Brieva, Ester Moral-Torres, Antonio Cano, Elvira Munteis, Juan Navarro-Barriuso, Eva M. Martínez-Cáceres, Cristina Ramo-Tello

Research output: Contribution to journalArticleResearch

1 Citation (Scopus)

Abstract

© 2019 Bibiana Quirant-Sánchez et al. Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1CM cells (relapsed: 11 60 ± 4 17%vs. nonrelapsed: 9 25 ± 3 17%, p < 0 05) and Th1Th17CM cells (relapsed: 15 65 ± 6 15%vs. nonrelapsed: 10 14 ± 4 05%, p < 0 01) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17CM (CD4+CCR7+CD45RA-CCR6+CXCR3+) cells > 11 48% had a 50% relapse-free survival compared to patients with Th1Th17CM cells < 11 48% whose relapse-free survival was 88% (p = 0 013, log-rank test). Additionally, a high percentage of Th1Th17CM cells was also found in patients with MRI activity (MRI activity: 14 02 ± 5 87%vs. no MRI activity: 9 82 ± 4 06%, p < 0 01). Our results suggest that the percentage of Th1Th17CM lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment.
Original languageEnglish
Article number8147803
JournalMediators of Inflammation
Volume2019
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint Dive into the research topics of 'Th1Th17<inf>CM</inf> lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment'. Together they form a unique fingerprint.

  • Cite this

    Quirant-Sánchez, B., Presas-Rodriguez, S., Mansilla, M. J., Teniente-Serra, A., Hervás-García, J. V., Brieva, L., Moral-Torres, E., Cano, A., Munteis, E., Navarro-Barriuso, J., Martínez-Cáceres, E. M., & Ramo-Tello, C. (2019). Th1Th17<inf>CM</inf> lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment. Mediators of Inflammation, 2019, [8147803]. https://doi.org/10.1155/2019/8147803